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Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the viral strain that has caused the coronavirus disease 
2019 (COVID-19) pandemic, has presented healthcare systems around the world with an unprecedented challenge. In loca-
tions with significant rates of viral transmission, social distancing measures and enforced ‘lockdowns’ are the new ‘norm’ as 
governments try to prevent healthcare services from being overwhelmed. However, with these measures have come important 
challenges for the delivery of existing services for other diseases and conditions. The clinical care of patients with pituitary 
disorders typically involves a multidisciplinary team, working in concert to deliver timely, often complex, disease investiga-
tion and management, including pituitary surgery. COVID-19 has brought about major disruption to such services, limiting 
access to care and opportunities for testing (both laboratory and radiological), and dramatically reducing the ability to safely 
undertake transsphenoidal surgery. In the absence of clinical trials to guide management of patients with pituitary disease 
during the COVID-19 pandemic, herein the Professional Education Committee of the Pituitary Society proposes guidance 
for continued safe management and care of this population.
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Introduction
In many centers worldwide, the evaluation and treat-
ment of pituitary disorders has already been substantially 
impacted by severe acute respiratory syndrome coronavirus 
2 (SARS-CoV-2), the viral strain that has caused the coro-
navirus disease 2019 (COVID-19) pandemic. With reduced 
access to routine clinical services, patients with suspected 
or confirmed pituitary disease face the prospect of delays 
in diagnosis and implementation of effective treatment 
plans. Furthermore, patients undergoing surgery may be at 
increased risk from COVID-19, whilst the risk of infection 
to healthcare providers during pituitary surgery is of par-
ticular concern.
Herein, we discuss several clinical scenarios where clini-
cal care can be adjusted temporarily without compromising 
patient outcomes. For this expert guidance, The Pituitary 
Society Professional Education Committee, which includes 
neuroendocrinologists and neurosurgeons from four conti-
nents, held an online video conference call with subsequent 
discussions conducted through email communications. The 
suggestions are not evidence-based due to the novelty and 
timing of the pandemic; furthermore, re-evaluation every 
few months in light of emerging data, is recommended. 
The approach will also likely vary from country to coun-
try depending on the risk of viral infection, local rules for 
“lockdown”, and the capabilities of individual health care 
systems.
Pituitary surgery challenges during the COVID‑19 
pandemic
The significant challenges to pituitary surgery presented by 
COVID-19 can be considered in terms of the phase of the 
pandemic, the patient, the surgeon, and the healthcare insti-
tution (Table 1).
The World Health Organization (WHO) recognizes sev-
eral phases of a pandemic wave [1]. When the pandemic is in 
progress (WHO pandemic phase descriptions; Phase 6) [2] 
there is a high prevalence of active cases. In the immediate 
post-peak period, the pandemic activity appears to wane, but 
active cases remain, and additional waves may follow. Previ-
ous pandemics have had many such waves, each separated by 
several months (www.cdc.gov). The corollary is that there 
will remain a significant possibility of patients and surgeons 
contracting COVID-19 until a vaccine is developed or herd 
immunity is achieved by other means.
The patient requiring pituitary surgery may be espe-
cially vulnerable to COVID-19 due to age and/or comor-
bidities. This is particularly true of patients with func-
tioning pituitary adenomas such as those with Cushing’s 
disease (CD), where cortisol excess results in immuno-
suppression, hypercoagulability, diabetes mellitus and 
hypertension, and acromegaly which is also frequently 
complicated by diabetes mellitus and hypertension. Moreo-
ver, the risk for patients undergoing surgery that develop 
COVID-19 in the perioperative period appears to be very 
Table 1  Pituitary surgery challenges and recommendations during COVID-19 pandemic
PPE personal protective equipment
*Depending on local guidance, chest CT is mandatory in some centers
Factor Challenges Recommendations
COVID-19 High prevalence of cases in the community during pandemic 
and risk of additional waves in the post-peak phase
Screening for cough, fever, and other symptoms and, if sus-
pected, swab for testing
Consider
 Isolation up to two weeks before surgery
 Paired swabs for testing and/or serological tests
 Chest X-ray and/or chest CT*
Patient High risk of older patients with comorbid conditions contracting 
COVID-19; consider natural history of pituitary disease
Emergency surgery if pituitary apoplexy, acute severe visual 
loss or other evidence of significant mass effect, or if there is 
concern regarding malignant pathology
Consider
 Surgery for patients with less acute, but progressive visual loss, 
functioning tumors with aggressive clinical features, and those 
with an unclear diagnosis
Surgeon Risk of surgeon contracting COVID-19 from patient In a patient with COVID-19 that requires emergent surgery that 
cannot be deferred, alternative transcranial approaches may be 
considered, drilling avoided, and full PPE is mandated
Consider
 Full PPE in all cases
Institution Diversion of resources to (non-pituitary) patients with COVID-
19
Maintain flexibility for second wave
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high. In a retrospective analysis of 34 patients who under-
went elective—non pituitary—surgeries during the incu-
bation period of COVID-19, 15 (44.1%) patients required 
admission to the intensive care unit, and 7 (20.5%) died [3]. 
Although this study included cases of variable technical 
difficulty, complexity and risk—from excision of breast 
lump to total hip replacement—we would suggest that 
patients undergoing pituitary surgery that develop COVID-
19 are likely to be at similar or greater risk. These risks 
must be balanced carefully against the natural history of 
pituitary disease and, in particular, whether undue delay 
may result in irreversible morbidity such as visual loss in 
patients with pituitary apoplexy.
The surgeon remains in direct contact with the patient 
throughout their operation and is therefore at risk of con-
tracting COVID-19 if the patient has an active infection. 
Iorio-Morin et al. [4] suggest that surgeons performing 
transsphenoidal pituitary surgery (TSS) may be at the great-
est risk, because such surgery is performed under general 
anesthesia, requiring intubation and extubation, exposes 
the colonized nasal mucosa, and usually involves sphenoid 
drilling, which can result in aerosolization of contaminated 
tissues.
The healthcare institution will invariably divert resources 
from elective services to support the care of patients with 
COVID-19, with a knock-on effect on the capacity to man-
age patients with pituitary disease (Table 1). Bernstein 
et al. [5] suggest that surgery is particularly affected in such 
reorganization, because of both the need for redeployment 
of anesthesiologists able to manage patient airways, and 
availability of protective physical resources such as masks, 
gowns, and gloves (personal protective equipment; PPE). 
Furthermore, in areas with high number of infections, sev-
eral operating rooms (OR)s were converted into intensive 
care units (ICU) to treat patients with COVID-19, thus limit-
ing patients’ access to elective surgery even more.
Recommendations for pituitary surgery
When the viral risk is decreasing in a specific geographic 
area, we would advocate a stepwise, but flexible normali-
zation of activity, addressing each of the aforementioned 
factors.
Burke et  al. [6] proposed a staged volume limiting 
approach to scheduling surgical cases depending on the 
number of community cases and inpatients with COVID-19, 
and staffing shortages. In extreme cases, where significant 
assistance is required from outside institutions, only emer-
gent cases can proceed.
Until further data become available, all patients 
undergoing pituitary surgery should undergo screen-
ing for COVID-19, until a vaccine is developed or herd 
immunity is achieved by other means. At the least, we 
recommend screening patients for cough, fever, or other 
recognized symptoms of infection with SARS-CoV-2, 
and taking swab samples for testing if there is any clini-
cal suspicion. Depending on the level of COVID-19 
activity in the community, and available resources, a 
more exhaustive strategy may be appropriate, including 
isolation of patients for up to 2 weeks before surgery, 
paired swabs and/or serological tests for all patients irre-
spective of symptoms, and routine chest X-ray or chest 
computed tomography (CT), depending on local guid-
ance. In patients with COVID-19 in whom surgery is 
indicated, in general we recommend delaying surgery if 
possible, ideally until patients no longer have symptoms 
and have a negative swab test result.
The nature of the patient’s pituitary disease is an impor-
tant consideration, and we propose stratifying cases as 
emergent, urgent, or elective. We recommend that patients 
continue to be operated on in an emergent fashion if they 
present with pituitary apoplexy, acute severe visual loss, or 
other significant mass effect, or if there is concern regard-
ing malignant pathology. Selected patients with slowly 
progressive visual loss, functioning tumors with aggres-
sive clinical features, and those with an unclear diagnosis, 
may also benefit from urgent (but not emergent) surgery, 
with decisions made on a case-by-case basis. Patients with 
incidental and asymptomatic tumors, known nonfunction-
ing adenomas [7] or functioning tumors, which are well 
controlled with medical therapy, can be scheduled as elec-
tive cases.
In most cases, TSS remains the safest, most effective, 
and most efficient approach to pituitary tumors. In a series 
of 9 consecutive patients without COVID-19 undergo-
ing pituitary and skull base surgery during the pandemic, 
Kolias et al. [8] reported that none of the patients or staff 
contracted COVID-19 following adoption of a standard-
ized risk-mitigation strategy. In the rare instances where a 
patient with COVID-19 requires emergent surgery that can-
not be deferred, alternative transcranial approaches may be 
considered (avoiding nasal mucosa). To replace high-speed 
drilling, the use of non-powered tools such as rongeurs and 
chisels has been recommended. If this is not possible large 
suction tubes can be used to aspirate as much particulate 
matter as possible [9]. In such cases, the availability and 
use of PPE, and in particular filtering facepiece (FFP3) res-
pirators, is mandated. Depending on the level of COVID-19 
activity in the community, and the availability and effective-
ness of testing, PPE may be appropriate in all cases.
At an institutional level, there must remain flexibility in 
anticipation of further waves of COVID-19. This necessi-
tates a reduction in capacity, particularly in available ICU 
beds, that must be recognized when scheduling challenging 
surgical cases. In the long term, resumption of full elec-
tive workloads depends on wider national and international 
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factors, including widespread testing, and widespread immu-
nity through vaccination or other means.
Pituitary diseases diagnosis and management
Acromegaly
Acromegaly, a condition that arises from growth hormone 
(GH) excess, generally occurs as a result of autonomous GH 
secretion from a somatotroph pituitary adenoma [10, 11], is 
associated with substantial morbidity and excess mortality, 
which can be mitigated by prompt and adequate treatment 
[12]. Diagnosis is often delayed because of the low preva-
lence of the disease, the frequently non-specific nature of 
presenting symptoms, and the typically subtle progression of 
clinical features [10, 11]. During the COVID-19 pandemic 
many outpatient clinics have closed or limited work hours. 
Patients are often reluctant to seek care out of fear of pos-
sible exposure to the coronavirus. Therefore, even longer 
diagnostic delays are anticipated. In addition, patients who 
present with vision loss and larger tumors encroaching upon 
the optic apparatus are at risk for experiencing persistent 
visual compromise unless the optic chiasm and nerves are 
promptly decompressed.
To improve patient access to care and minimize poten-
tially deleterious delays in diagnosis and treatment, clini-
cians may conduct virtual visits (VV) using secure, internet-
based electronic medical record platforms. A detailed history 
can be obtained and a limited physical examination is pos-
sible, including inspection of the face, skin and extremities.
Diagnosis
Establishing the diagnosis of acromegaly requires testing 
of serum insulin-like growth factor-I (IGF-I) levels [11] 
(Box 1). Access to accurate IGF-I assays is critical in light of 
the substantial analytical and post-analytical problems that 
have plagued several IGF-I immunoassays. While the oral 
glucose tolerance test (OGTT) is considered the diagnostic 
“gold standard”, this test is not essential in many patients, 
including those with a clear-cut clinical picture and an une-
quivocally elevated serum IGF-I level. Deferring the lengthy 
(2-h) OGTT may minimize the risk of potential exposure to 
infectious agents.
Given the over-representation of macroadenomas in 
patients with acromegaly, pituitary imaging is indicated, 
preferably by a pituitary-specific magnetic resonance imag-
ing (MRI) protocol, although CT may be performed to rule 
out a large tumor if MRI is not feasible. Obtaining imag-
ing at satellite sites detached from major hospitals may also 
decrease the risk of infection exposure.
Management
Transsphenoidal pituitary surgery remains the treatment 
of choice for most patients with acromegaly [10, 11], and 
patients with visual compromise as a result of a pituitary 
adenoma compressing the optic apparatus should still 
undergo pituitary surgery promptly. Other patients could 
be treated medically until the pandemic subsides. Medical 
treatment options are somatostatin receptor ligands (SRLs), 
octreotide long-acting release (LAR), lanreotide depot and 
pasireotide LAR, pegvisomant and cabergoline (used off-
label) [13]. Medical therapies can be effective in providing 
symptomatic relief, control GH excess or action, and poten-
tially reduce tumor size (except pegvisomant, which does not 
have direct antiproliferative effects). Preoperative medical 
therapy has been reported to improve surgical outcomes in 
some, but not all studies. Pasireotide, which potentially can 
induce QTc prolongation, should be used with caution in 
patients who are taking, either as prophylaxis or treatment, 
medications for COVID-19 (azithromycin, hydroxychlo-
roquine), which can also have an effect on QTc interval. 
Furthermore, as hyperglycemia is very frequent in patients 
treated with pasireotide and needs close monitoring at start 
of the treatment, this treatment should be reserved for truly 
resistant cases, with large tumors and who cannot have sur-
gery yet. Notably, lanreotide depot, cabergoline or pegviso-
mant can be administered by the patient or a family member 
and therefore an in-person visit to a clinic is not required. 
If SRLs that require health care professional administration 
are required, raising the dose may allow the interval between 
injections to be extended beyond 4 weeks while maintaining 
disease control. Virtual visits can be implemented to monitor 
the patient’s course and response to medical therapy during 
the pandemic. Careful management of comorbidities asso-
ciated with acromegaly remains an essential part of patient 
care [14, 15].
Prolactinomas
Hyperprolactinemia may be physiological in origin or 
arise because of an underlying pathophysiologic cause, 
medication use or laboratory artifact. Therefore, an initial 
evaluation for hyperprolactinemia should include a com-
prehensive medication history, a thorough evaluation for 
secondary causes, including primary hypothyroidism, and 
a careful assessment for clinical features of hyperprolactine-
mia, including hypogonadism and galactorrhea. Unless a 
secondary cause of hyperprolactinemia can be established 
definitively, further investigation is indicated to evaluate the 
etiology of hyperprolactinemia.
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Diagnosis
The diagnosis of a lactotroph adenoma can be inferred in 
most patients based on the presence of a pituitary adenoma 
and an elevated prolactin level, which is typically propor-
tionate in magnitude to adenoma size. Pituitary imaging 
(MRI or CT) is therefore a key step in the investigation of 
hyperprolactinemia. Evaluation for hypopituitarism is also 
necessary.
Management
Although observation and routine follow-up with serial 
prolactin levels and imaging is acceptable for patients who 
are asymptomatic and who have a microadenoma, most 
patients diagnosed with a prolactinoma will require treat-
ment. Dopamine-agonists (DA) can normalize prolactin lev-
els and lead to reduction in size of the lactotroph adenoma 
[16]. In patients who have a microadenoma and who are 
not seeking fertility, hormone-replacement therapy may also 
be appropriate if serum prolactin is routinely followed and 
imaging performed as necessary.
Medical therapy can be managed effectively and effi-
ciently via VVs coupled with laboratory/imaging studies as 
needed. However, in all patients in whom a DA will be initi-
ated, it is critical that a comprehensive psychiatric history 
is obtained prior to commencing treatment. Patients may 
not readily volunteer their psychiatric history and may not 
appreciate the relevance of such information. For example, 
until specifically questioned about their psychiatric history, 
the patient described in the illustrative case (Box 2) did not 
report a history of severe depression, suicide attempt and 
prolonged psychiatric hospitalization 8 months prior to pres-
entation with hyperprolactinemia. At the time of the visit, 
he was not taking any psychiatric medications and was not 
under the care of a mental health team. Given this patient’s 
significant psychiatric history, lack of ongoing psychiatric 
care, and the well-recognized adverse effects of DA therapy, 
including increased impulsivity, depression and psychosis 
[17], a DA was not initiated. Counseling on potential DA 
side-effects is crucial, as they may also present in individu-
als with no prior psychiatric history [17]. Furthermore, 
during the COVID-19 pandemic when there is reduced 
access to routine medical and mental health care, patients 
who develop symptoms of severe depression may not have 
ready access to mental health services, or may not seek care. 
Therefore, it is particularly important to make patients aware 
of these potential side effects and the critical importance of 
reporting them.
In the small number of patients for whom medical therapy 
is not possible and where surveillance is not appropriate 
(e.g., macroprolactinoma with visual loss) the risks and 
benefits of surgical intervention will need to be carefully 
weighed.
Cushing’s disease
Left untreated, CD has significant morbidity and mortal-
ity, and delays in diagnosis (from a few months to even 
years) are common. Clinical presentation is also very vari-
able with some patients having subtle symptoms while oth-
ers present with more striking/classical features. Severe 
hypercortisolemia induces immunosuppression, which may 
place patients with untreated CD at particular risk from 
COVID-19.
New patients referred for endocrinology evaluation 
with clinical suspicion of Cushing’s
Diagnosis
Screening for, and confirmation of Cushing’s syndrome 
(CS) and, furthermore, localization for CD is laborious and 
requires serial visits and testing procedures [18, 19]. If ini-
tial laboratory abnormalities are consistent with hypercorti-
solemia, a VV should allow for an estimate of the severity of 
clinical presentation and facilitate planning for further test-
ing and treatment. Careful questioning for potential causes 
of exogenous CS (including, but not limited to, history of 
high-dose oral corticosteroids, intraarticular injections 
or topical preparations) is an important first step. Subse-
quently, establishing the likelihood and pretest probability 
of CS is more important than ever now, when testing may 
be delayed. While presentation varies significantly between 
patients, some features, although not all highly sensitive, are 
more specific, e.g. easy bruising, facial plethora, large wide 
> 1 cm violaceous striae, proximal weakness and hypoka-
lemia. Diagnosis of CS is often challenging even under 
normal circumstances, however, a diagnosis by VV is more 
nuanced and difficult. Conversely, if a patient has a high like-
lihood of CS, we recommend limited laboratory evaluation 
(urinary free cortisol (UFC), adrenocorticotropic hormone 
(ACTH), liver panel, basic metabolic panel), preferably at 
a smaller local laboratory rather than a Pituitary Center, to 
reduce viral risk exposure. Salivary cortisol samples could 
represent a hazard for laboratory staff and they are prohib-
ited in some countries [18, 19]. In the US, laboratories have 
continued to process salivary cortisol samples and salivary 
cortisol has higher sensitivity compared with UFC and has 
the convenience of mailing multiple specimens at a time, 
without travel [18, 19]. Though usually we strongly recom-
mend sequential laboratory testing under normal circum-
stances, limiting trips to a laboratory is preferred during 
COVID-19.
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If preliminary assessment confirms ACTH-dependent 
CS [18, 19] and no visual symptoms are reported, imaging 
may be delayed. However, in the presence of any visual 
symptoms, and recognizing the challenges of undertaking 
a formal visual field assessment, proceeding directly with 
MRI or CT (shorter exam time and easier machine access) 
imaging, will allow confirmation or exclusion of a large 
pituitary adenoma compressing the optic chiasm. If the 
latter is confirmed, the patient will need to be evaluated 
by a neurosurgeon. In contrast, a small pituitary adenoma 
may not be visible on CT, but in such cases MRI may be 
deferred for a few months until COVID-19 restrictions 
limiting access to care are lifted.
Another VV will help to decide, in conjunction with 
patient’s preference, the best next step, which in cases of 
more severe clinical Cushing’s, and in the absence of a 
large pituitary adenoma, would be medical therapy. The 
magnitude of 24 h-UFC elevation could also represent a 
criterion for primary therapy, since higher values have 
been associated with increased risk of infection.
In parallel, it is also important to address comorbidi-
ties including diabetes mellitus, hypertension and hyper-
lipidemia. In light of the increased risk of venous throm-
boembolism, in discussion with primary care providers, 
plans for regular mobilization/exercise as permitted 
(including at home when orders to stay in are in place) 
and/or prophylactic low weight molecular heparin should 
be considered.
Management
First line medical therapy options vary, depending on 
country availability, regulatory approval and patient 
comorbidities. Ideally, an oral medication, which is easier 
to administer is preferred; options include ketoconazole, 
osilodrostat or metyrapone [20, 21]. Cabergoline therapy, 
which has lesser efficacy [20, 21] compared with adre-
nal steroidogenesis inhibitors, can be also attempted in 
very mild cases. The initial laboratory profile should be 
reviewed to exclude significant abnormalities of renal 
and/or liver function prior to commencing treatment. 
Starting doses of all medications should be the lowest 
possible to avoid adrenal insufficiency (AI) and up titra-
tion should be slow, with VVs weekly if possible. All 
patients with CS on any type of medical therapy should 
have prescribed glucocorticoids (GC) both in oral and 
injectable forms available at home and information 
regarding AI should be provided during a VV when start-
ing therapy for CS. Down titration of other medications 
for diabetes and hypertension may also be needed over 
time. Pasireotide (both subcutaneous and LAR prepara-
tions) would be a second line option, reflecting higher 
risk of significant hyperglycemia that would require treat-
ment [22].
If the clinical features of CS are mild and longstand-
ing, with no acute deterioration, another possibility is to 
aggressively treat the associated comorbidities for a few 
months; depending on local circumstances, this may actu-
ally be less risky for the patient by avoiding the risk of AI/
crisis and the need for an emergency department (ED) visit 
and/or admission.
For patients with Cushing’s disease 
with endocrinology chronic care
Patients in remission after surgery with adrenal 
insufficiency on glucocorticoid replacement
These patients are likely to remain at slightly higher risk of 
COVID-19 infection due to immunosuppression from pre-
vious hypercortisolemia. Furthermore, GC doses should be 
adjusted to prevent adrenal crisis and visits to an ED. Lower 
GC daily doses (10–15 mg hydrocortisone/day) are now fre-
quently used for replacement and virtual and/or phone visits 
are encouraged to evaluate an appropriate regimen and suf-
ficient supplies of medication and injectable GC (at home) 
should be prescribed. Patients with potential symptoms of 
under replacement may require an increase in daily dose, 
while balancing any risk of GC over replacement and pos-
sible consequent immunosuppression.
Patients in non‑remission treated with medical therapy 
(dependent on country availability)
Doses may need to be adjusted to reduce the risk of AI/crisis 
and reduce the need for serial laboratory work. Monthly or 
bimonthly VVs are appropriate for clinical evaluation and 
up titration should be slower than usual. Patients with CD 
on medical therapy need to have at home prescriptions for 
oral and injectable GC and instruction on AI surveillance. 
Patients should also be advised, that if they develop a fever, 
to stop Cushing’s medication for few days; if they develop 
AI symptoms, GC administration will be required. In some 
countries, block and replace regimens are also employed to 
avoid risk of AI. Of note, for mifepristone, a glucocorticoid 
receptor (GR) antagonist, patients will require much higher 
doses of GC to reverse the blockade (1 mg of dexamethasone 
approximately per 400 mg of mifepristone) and for several 
days, as drug metabolites also have GR antagonist effects.
Furthermore, for all patients who have made dose changes 
or discontinued medications for Cushing’s, it is essential 
to follow very closely and consider adjustments in the 
doses of concomitant medications, especially insulin, other 
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antidiabetic and antihypertensive medications, and potas-
sium supplements.
If patients have history of radiotherapy and are still on 
medications for CD, a VV every few months should be 
performed to determine if anti-Cushing’s treatment can be 
slowly down-titrated (to avoid AI). A morning serum corti-
sol would be ideal to rule out AI off medications, however, 
if laboratory testing cannot be undertaken safely, clinical 
evaluation by serial VVs can be helpful. While head-to-head 
data will never be available, in COVID-19 hotspots, given 
the higher risk of infection with laboratory testing or face to 
face visits, mild hypercortisolemia might be “better” than 
adrenal crisis, especially in the short term!
Patients with CD have increased rates of depression, anxi-
ety and can have decreased quality of life (QoL) even when 
in long-term remission, thus in the challenging circum-
stances of the current pandemic it is it even more important 
to focus on psychological evaluation during virtual endocri-
nology visits, with referral to virtual counseling as needed.
Box 2 Prolactinoma—illustrative case
Clinical case: A 38-year-old man presented with a two-
year history of fatigue and low libido. An 8 AM tes-
tosterone level was low at 225 ng/dL (reference range; 
250–1100 ng/dL) and a prolactin level was subsequently 
found to be 700 ng/mL (reference range; < 20 ng/mL). 
Pituitary MRI demonstrated a 1.2 cm pituitary adenoma 
with suprasellar extension, abutting, but not compress-
ing, the optic chiasm. After further discussion with the 
patient, a long-standing history of severe psychiatric 
disease, not treated at this time, is revealed.
Question: How should this patient be managed in the 
setting of an ongoing pandemic?
Case follow-up: Given the size of the lesion 
(> 1 cm), laboratory studies for hypopituitarism were 
recommended and other than low testosterone, pitui-
tary function was normal. He was referred for neuro-
surgical evaluation, the therapeutic option of choice if 
DAs are contraindicated or not effective. Unless visual 
field abnormalities or deficits become apparent in the 
interim, given the potential surgery risk, this patient 
could also be closely monitored while safely deferring 
surgery by repeating a prolactin level and pituitary MRI 
in 3 months.
TSH‑secreting pituitary adenomas
Thyroid stimulating hormone (TSH)-secreting pituitary 
adenomas are a rare but important cause of hyperthyroid-
ism (estimated prevalence 2.8 per million population) [23, 
24]. Clinical features resemble those observed in primary 
hyperthyroidism but without disease-specific (e.g. Graves 
ophthalmopathy) manifestations [24, 25]. Visual disturbance 
may complicate macroadenomas with suprasellar extension, 
whilst hormonal co-secretion (e.g. GH, prolactin) and/or 
hypopituitarism may also be evident [24, 25].
Diagnosis
A major challenge in the diagnostic pathway is the exclu-
sion of other common (e.g. laboratory assay interference, 
confounding medications, intercurrent illness) and rarer (e.g. 
THRB resistance to thyroid hormone; THRB RTH) causes of 
hyperthyroxinemia with non-suppressed TSH [25, 26]. This 
distinction remains important; avoid inappropriate investi-
gation and treatment, and begin with a careful reappraisal 
of the clinical history and medications. Laboratory assay 
Box 1 Acromegaly—illustrative case
Clinical case: A 52-year-old man presented with several 
months’ history of frequent, frontal headaches that per-
sisted despite trials of preventive therapies, including 
amitriptyline and topiramate. He had been diagnosed 
with hypertension and sleep apnea 2 years prior but 
had no known diabetes mellitus. He was taking lisino-
pril and topiramate. His neurologist obtained a brain 
MRI examination, which demonstrated a sellar mass 
consistent with an adenoma, measuring 1.2 cm in great-
est diameter; the tumor was not impinging on the optic 
chiasm. His primary care physician noticed coarsen-
ing of patient’s facial features in comparison with older 
photographs and referred him to an endocrinologist.
Question: How should this patient be evaluated and 
managed in the setting of an ongoing pandemic?
Case follow-up: The patient had an elevated serum 
IGF-I level, which was 2.5 times above the upper end 
of the reference range (xULN). There was no laboratory 
evidence of other pituitary hormone deficits. Treatment 
with lanreotide depot 120 mg every 4 weeks, which is 
easier to self -administer or be administered by a fam-
ily member, led to substantial improvement in head-
aches and IGF-I normalization within 12 weeks. He 
was referred to consult with an expert neurosurgeon and 
discuss undergoing TSS electively, when this becomes 
feasible.
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interference should be actively sought [25–27] and labora-
tories should be aware of the specific concern (e.g. serum 
dilution studies or polyethylene glycol (PEG) precipitation 
to exclude a spurious TSH result in the context of primary 
thyroid disease) [26, 27].
In a patient with visual disturbance suggestive of optic 
chiasmal compression and genuine hyperthyroxinemia with 
non-suppressed TSH (± evidence of other pituitary dysfunc-
tion), pituitary imaging should be performed (either MRI or, 
depending on local circumstances, dedicated pituitary CT) 
to confirm the presence of a macroadenoma with suprasellar 
extension.
In a patient without evidence of visual pathway compro-
mise or associated hypopituitarism, a local decision will 
need to be made whether to attempt further investigation or 
defer until the COVID-19 pandemic subsides (in which case 
empiric treatment should be considered—see below). When 
further investigation is considered appropriate, the reader is 
directed to other publications that consider in detail how to 
discriminate between a TSH-secreting adenoma and THRB 
RTH [25–27].
Management
As with other anterior pituitary tumor subtypes, the goals 
of treatment are control of hormone excess, amelioration of 
compressive symptoms and correction of hypopituitarism 
[24, 25, 28]. For patients with a macroadenoma and visual 
compromise, early surgical intervention remains the treat-
ment of choice, once appropriate medical therapy has been 
instituted to mitigate the risks of anesthesia in a patient with 
uncontrolled thyrotoxicosis.
Medical treatment options depend on the clinical context. 
When a diagnosis is clear, first generation SRLs, e.g. octreo-
tide LAR, lanreotide depot (which may constitute off-label 
use in some countries) are effective in rapidly correcting 
hyperthyroxinemia in the majority of patients (typically 
within few weeks). Such medications may be deployed in 
preparation for surgery or as primary medical therapy until 
surgery becomes feasible (NB; tumor shrinkage is variable 
with SRL therapy, and surgery therefore remains the best 
treatment to rescue/preserve vision). As with acromegaly, 
DA therapy (e.g. cabergoline used off-label) may be effective 
in some cases (especially when there is genuine prolactin 
co-secretion).
For those patients in whom diagnosis is suspected, but not 
confirmed, a SRL trial may prove both diagnostic and thera-
peutic. Alternatively, and especially in those with palpita-
tions/arrhythmias or those deemed at risk of cardiovascular 
complications, non-selective beta-blockers are a reasonable 
option (with non-dihydropyridine calcium channel block-
ers reserved for those in whom beta-blockade is contrain-
dicated). Appropriate consideration must also be given to 
anticoagulation in those subjects with atrial fibrillation, who 
are likely to be at the same excess risk of thromboembolic 
events as patients with primary thyroid disease.
A role for conventional anti-thyroid drug therapy in the 
management of TSH-secreting pituitary adenomas remains 
controversial, as tumor expansion is at least theoretically 
possible, although short-term usage, especially in those with 
a microadenoma, may be appropriate in some cases (e.g. 
when there is resistance to SRL therapy).
Hypopituitarism
Clinicians need to remain vigilant in managing patients with 
hypopituitarism during the COVID-19 pandemic. There is 
an increased background mortality rate among patients with 
hypopituitarism, particularly due to cerebrovascular and car-
diovascular disease, which is an important risk factor for 
COVID-19 disease severity [29, 30]. There is also a careful 
balance in managing the threat of AI at this time with pro-
longed GC over-replacement and consequent immunosup-
pression. Patients with diabetes insipidus (DI) present a par-
ticular challenge in fluid balance during significant illness, 
with hypernatremia linked to increased mortality in those 
admitted to intensive care units [31].
Diagnosis
In a patient with a newly detected pituitary lesion or sus-
pected hypopituitarism, an early morning fasted pituitary 
profile should be arranged promptly with a local laboratory 
and results can be discussed at a VV. If DI is strongly sus-
pected based on clinical history a non-fasted morning blood 
sample for serum sodium and osmolality should be collected 
first. Patients with complete DI often present with hyper-
natremia in this setting, avoiding the need for a protracted 
water deprivation test. A cortisol level < 3 µg/dL indicates 
AI while a cortisol level > 15 µg/dL reliably excludes AI 
[29]. Dynamic testing is ordinarily performed to determine 
adequacy of the hypothalamic–pituitary–adrenal axis with 
intermediate results, however there may be a significant 
delay in obtaining a short cosyntropin test, or insulin tol-
erance test, at this time with health care systems limiting 
direct exposure of patients to health care personnel. A low 
free T4 in concert with a low/normal TSH is suggestive of 
central hypothyroidism. In non-obese males with a pituitary 
lesion, low serum testosterone and low/normal gonadotro-
phins likely indicate central hypogonadism. Low estradiol 
with low/normal gonadotrophins in a pre-menopausal 
woman with amenorrhea (excluding other causes such as 
hypothalamic amenorrhea and hyperprolactinemia) or in a 
post-menopausal female also suggest central hypogonadism. 
Growth hormone deficiency is highly likely (even with a 
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normal IGF-1 level) to co-exist in a patient with deficiencies 
of 3–4 pituitary axes although dynamic testing to confirm 
GH deficiency should be deferred for 6–12 months until spe-
cialized endocrine testing units are once again conducting 
these non-urgent procedures.
Management
The safest option is to commence hydrocortisone replace-
ment with 15–25 mg/day in divided doses. While over 
replacement is always important to avoid, in areas with 
high risk of viral exposure, it would be preferable to err on 
the side of starting on the higher end of this dose range to 
ensure no under replacement. Given the risk of an adrenal 
crisis with COVID-19 (or any other illness), all patients on 
GC should be reminded about sick day management [32]. 
This includes prompt doubling of their regular GC dose at 
the first sign of sickness, ensuring access to injectable GC 
and use of medical alert jewelry. Where medication supply 
may become an issue, it would be reasonable to make sure 
patients have 2–3 months reserves of their GC therapy and 
there may be a need to switch between GC preparations (for 
example hydrocortisone to cortisone acetate or prednisone 
depending on country approvals) if availability becomes 
limited. Adequate GC management can be assessed clini-
cally by VV.
Once GC is started, it would be safe to commence thy-
roid replacement if required. A reasonable starting dose, in 
the absence of coexistent significant cardiac disease, would 
be approximately 50–75 µg levothyroxine daily, but dose is 
usually weight-based. Dose adjustment, and clinical reas-
sessment, can take place via VV, aiming for a free T4 level 
in the mid-upper normal range [29]. Ideally, free T4 levels 
would be assessed 6–8 weeks later, however deferring for 
3–4 months would be reasonable.
Testosterone or estrogen replacement could also reason-
ably be deferred for 6 months, although if there are sig-
nificant symptoms persisting after GC and thyroid replace-
ment, commencement of transdermal preparations would be 
advised over injectable testosterone to again limit the need 
for patients to visit primary care physicians. GH replacement 
is usually deferred in a patient with an untreated sellar mass. 
In patients already established on gonadal or GH replace-
ment, clinical assessment to avoid side effects would be 
adequate, although it may be appropriate to ensure adequate 
testosterone levels in men and maintenance of IGF-1 below 
the age-adjusted upper normal reference level whenever 
essential biochemical testing is performed [29].
In patients with DI without concomitant illness the main 
risk is iatrogenic hyponatremia [29]. If access to regular 
electrolyte monitoring is difficult it would be prudent to 
advise patients to withhold a weekly dose of desmopres-
sin to allow for an aquaresis and favor under-dosing during 
daytime, with an aim to relieve symptoms of polyuria par-
ticularly overnight. In those with mild or partial DI, treat-
ment with desmopressin may not be required as long as 
patients are instructed to drink to thirst and have access to 
fluids. In hospitalized patients, hypernatremia is more likely 
to occur, particularly in those with adipsic DI, as patients 
may have reduced fluid intake, fever may increase water 
losses and oral desmopressin dosing may be more difficult. 
Regular electrolyte monitoring is required, with requirement 
for parenteral desmopressin and intravenous fluids in cases 
of severe illness.
Conclusion
Taking care of patients with pituitary disorders typically 
involves a multidisciplinary approach in order to achieve 
timely, often complex, diagnostic and treatment plans, 
including pituitary surgery. The COVID-19 pandemic has 
significantly limited, in many regions, patients’ access to 
testing (laboratory and imaging), and severely decreased the 
capability to safely perform transsphenoidal surgery. Clini-
cians have expanded VV and new criteria and processes are 
being applied to stratify patients’ needs both for medical 
therapy and pituitary surgery.
The guidance provided here is based on rapid expert con-
sensus of the Pituitary Society Professional Education Com-
mittee, however, due to the emerging nature of the COVID-
19 crisis, information can change very rapidly. Providers and 
patients alike need to always consider individual patients’ 
conditions, and local country and region particularities, both 
for viral load and healthcare availabilities when devising 
individualized patient management plans.
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